

MAR-02-00 12:32 From:

T-301 P.05/07 Job-482

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: DIET DRUGS (Phentermine/
Fenfluramine/Dexfenfluramine) : MDL Docket No. 1203
PRODUCTS LIABILITY LITIGATION :

PRETRIAL ORDER NO. 1162

(Designation of Treating Physicians
As Case-Specific Experts)

This Order will govern the designation of treating physicians as case-specific experts in all cases that are part of this coordinated proceeding.

Pursuant to Pretrial Order No. 417, Plaintiffs are required to designate case-specific experts who are expected to testify as to any issue other than economic damages. In addition to identifying these experts, Pretrial Order No. 417 requires Plaintiffs to provide all expert disclosures in accordance with Fed. R. Civ. P. 26(a)(2).

The Special Discovery Master has informed the Court that some Plaintiffs have failed to designate as experts treating physicians who intend to give opinion testimony regarding causation. Absent proper disclosures, Defendants are denied an adequate opportunity to prepare for the depositions of these experts.

Although most Plaintiffs have identified treating physicians in their fact sheets, this identification does not meet the expert disclosure requirements of Pretrial Order No. 417 or Fed. R. Civ. P. 26(a)(2). As such, any Plaintiff who intends to rely

MAR-02-00 12:32 From:

T-301 P.06/07 Job-482

upon a treating physician as a causation expert must designate the physician as a case-specific expert and provide all Fed. R. Civ. P. 26(a)(2)(B) disclosures pursuant to the deadlines established by Pretrial Order No. 992.

In those cases where Plaintiffs have designated by name their treating physicians as case-specific experts within the established deadlines but have failed to provide the disclosures required by Fed. R. Civ. P. 26(a)(2)(B), Plaintiffs shall serve complete expert disclosures within thirty (30) calendar days of the date of this Order.

For those cases with Discovery Initiation Dates ("DIDs") up to and including October 1, 1998, where the deadlines for designating case-specific experts have expired, Plaintiffs may designate their treating physicians as case-specific experts in accordance with the following conditions:

1. Plaintiffs may designate as case-specific experts only those physicians previously identified in their fact sheets as treating physicians;
2. Plaintiffs must designate their treating physicians as case-specific experts within fourteen (14) calendar days of the date of this Order;
3. Plaintiffs must provide all expert disclosures, as required by Fed. R. Civ. P. 26(a)(2)(B), for those treating

MAR-02-00 12:32 From:


T-301 P.07/07 Job-482

physicians designated as case-specific experts within thirty (30) calendar days of the date of this Order; and

4. In those situations where Defendants have deposed previously the treating physician who is now designated as Plaintiff's case-specific expert pursuant to this Order, as a fact witness after the deadline for disclosure, Defendants may redepose this physician with Plaintiff to bear the costs, including reasonable expert fees, counsel fees and expenses. Plaintiffs shall not bear the costs for Defendants to depose a treating physician not yet deposed by the Defendants.

The Special Discovery Master will establish deadlines in addition to those set forth herein for completing the depositions of all related case-specific experts and for Defendants to provide responsive expert designations and disclosures.

BY THE COURT:


BECHTLE, J.

Date: February 18, 2000

EXHIBIT 5

OCT 23 2003 14:43 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.04/21

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: DIET DRUGS
(PHENTERMINE, FENFLURAMINE,
DEXFENFLURAMINE) PRODUCTS
LIABILITY LITIGATION

MDL DOCKET NO. 1203

THIS DOCUMENTS RELATES TO:

PEGGY MARTINEZ

vs.

AMERICAN HOME PRODUCTS
CORPORATION, ET AL


CIVIL ACTION NO. 02-20135

PLAINTIFFS' DESIGNATION OF CASE SPECIFIC
EXPERT AND REPORT

In accordance with Fed. R. Civ. P. 26(a)(2) and applicable Pretrial Orders,
Plaintiff hereby designates that Plaintiff may call to testify in the above-referenced case
the case specific expert witness, Dr. Chester Falterman. The report of the expert witness
is attached hereto.

Respectfully submitted,

O'QUINN, LAMINACK & PIRTLE


SUSAN EARNEST (LA# 22348)
RICHARD N. LAMINACK (TBA #11850350)
THOMAS W. PIRTLE (TBA #16038610)
440 Louisiana, Suite 2300
Houston, Texas 77002
(713) 223-1000
(713) 223-4870 (fax)

ATTORNEYS FOR PLAINTIFF

OCT 23 2003 14:43 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.05/21

CERTIFICATE OF SERVICE

I hereby certify that a true and correct copy of the foregoing document has been forwarded via Regular United States Mail to all counsel of record on this 23 day of October, 2003.

Michael T. Scott
REED SMITH, L.L.P.
2500 One Liberty Place
Philadelphia, Pennsylvania 19103
Telephone: 215/851-8248
Facsimile: 215/851-1420

**LIASON COUNSEL OR FENFLURAMINE AND DEXFENFLURAMINE
DEFENDANTS**

Edward W. Madeira, Jr.
PEPPER HAMILTON, L.L.P.
Bell Atlantic Building, 34th Floor
1717 Arch Street
Philadelphia, Pennsylvania 19103
Telephone: 215/981-4353
Facsimile: 215/981-4307

LIASON COUNSEL FOR PHENTERMINE MANUFACTURERS AND SUPPLIERS

Edward S. Weltman
GOODWIN PROCTOR, L.L.P.
1285 Avenue of the Americas
New York, New York 10019
Telephone: 212/956-1500
Facsimile: 212/956-3252

CO-LEAD COUNSEL FOR PHENTERMINE DEFENDANTS

Peter L. Resnick
McDERMOTT, WILL & EMERY
28 State Street, 34th Floor
Boston, Massachusetts 02109-1775
Telephone: 617/535-4000
Facsimile: 617/535-3800

OCT 23 2003 14:43 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.06/21

CO-LEAD COUNSEL FOR PHENTERMINE DEFENDANTS

Mr. John J. Disimone, III
Plaintiffs' Management Committee
Diet Drugs Products Liability Litigation
325 Chestnut Street, Suite 200
Philadelphia, Pennsylvania 19106

PLAINTIFFS' MANAGEMENT COMMITTEE


SUSAN EARNEST

OCT 23 2003 14:43 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.07/21

Heart Clinic
of Louisiana

ECHO SECTOR REPORT

NAME: Peggy H. Martinez DATE: 11/18/97
 DOCTOR: Dr. Falterman AGE/SEX: 48/F
 HOSPITAL # CLINIC # 75550
 INDICATIONS: SOB.

A Professional
Medical Corporation

Frederick C. Kushner, MD
Medical Director
G. Brian Melton, MD
Medical Director

Chester J. Falterman, MD
E. Kenneth Kout, MD
Leslie W. Lavenex, MD
Louis B. Chade, MD
David R. Hutchinson, MD

HISTORY:

PAST HISTORY:

MEASUREMENTS

(NORMALS)		
(7-28)MM	RVD	23
(30-53)MM	LVEDD	57
	LVEDS	38
(>25%)	F.S.	33
(6-11)MM	IVE	7
(6-10)MM	LVPW	7
(20-37)	AORTIC ROOT	31
(15-26)MM	AV EXCURSION	23
(19-40)MM	LAD	36
(0-8)MM	MITRAL E POINT SEPTAL SEPARATION:	5
(>45)	EF SLOPE	

TECH NOTES:

INTERPRETATION: This is technically a good quality study. The left atrium, aortic root, right atrium and right ventricle are normal. The left ventricle is minimally dilated to 5.7 cm. Left ventricular wall motion and systolic function are normal. There is no pericardial effusion. The aortic, tricuspid, mitral and pulmonic valves are morphologically normal.

1111 Medical Center Blvd.
N 613
Metairie, LA 70002-0166
(504) 885-6600
Fax - (504) 885-6621

110 Meadowcrest St.
Suite 410
Covington, LA 70038-3220
(504) 394-9462
Fax - (504) 394-0273

MARTINEZ

101321--;006

0024

OCT 23 2003 14:43 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.08/21

Page -2-

NAME: Peggy H. Martinez
CLINIC# 75550
DATE: 11/18/97

CONCLUSION: 1. MINIMAL DILATATION TO LEFT
VENTRICLE.
2. NORMAL LEFT VENTRICULAR SYSTOLIC
FUNCTION.



CHESTER J. FALTERMAN, M.D.

/sld

MARTINEZ-----

101321--;006

0025

OCT 23 2003 14:43 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.09/21



Heart Clinic
of Louisiana

CARDIAC DOPPLER

NAME: Peggy H. Martinez DATE: 11/18/97
DOCTOR: Dr. Falterman AGE/SEX: 48/F
HOSPITAL # CLINIC # 75550

INDICATIONS: SOB.

A. Prokhorov
Medical Corporation

EKG FINDINGS:

Frederick G. Kushner, MD
Medical Director
G. William McInnis, MD
Medical Director
Chester J. Falterman, MD
E. Kenneth Kessel, MD
Latha W. Levenson, MD
Loren S. Glade, MD
David B. Haskins, MD

TECH NOTES:

INTERPRETATION: Mitral inflow pattern is suggestive of abnormal relaxation and diastolic dysfunction. There is trace mitral insufficiency. There is mild aortic insufficiency. There is mild tricuspid insufficiency.

CONCLUSION: MILDLY ABNORMAL DOPPLER WITH COLORFLOW AS DETAILED ABOVE.

CHESTER J. FALTERMAN, M.D.

/sld

1111 Medical Center Blvd.
#413
Baton Rouge, LA 70802-3146
(504) 389-4600
Fax - (504) 389-4631

120 Magnolia Street
Suite 410
Covington, LA 70056-5220
(504) 394-9522
Fax - (504) 391-3023

MARTINEZ

101321---;006

0026

EXHIBIT 6

OCT 23 2003 14:44 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.12/21

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**


IN RE: DIET DRUGS	§	MDL DOCKET NO. 1203
(PHENTERMINE, FENFLURAMINE,	§	
DEXFENFLURAMINE) PRODUCTS	§	
LIABILITY LITIGATION	§	
	§	
THIS DOCUMENTS RELATES TO:	§	
	§	
MARILYN MELDER	§	
	§	
vs.	§	
	§	
AMERICAN HOME PRODUCTS	§	CIVIL ACTION NO. 02-20142
CORPORATION, ET AL		

**PLAINTIFFS' DESIGNATION OF CASE SPECIFIC
EXPERT AND REPORTS**

In accordance with Fed. R. Civ. P. 26(a)(2) and applicable Pretrial Orders,
Plaintiff hereby designates that Plaintiff may call to testify in the above-referenced case
the case specific expert witness, Dr. Gabriel Lasala. The curriculum vitae and written
report of the expert witness pursuant to Fed. R. Civ. P. 26(a)(2)(B) is attached hereto.

Respectfully submitted,

O'QUINN, LAMINACK & PIRTLE



SUSAN EARNEST (LA# 22348)
RICHARD N. LAMINACK (TRA #11850350)
THOMAS W. PIRTLE (TBA #16038610)
440 Louisiana, Suite 2300
Houston, Texas 77002
(713) 223-1000
(713) 223-4870 (fax)

ATTORNEYS FOR PLAINTIFF

OCT 23 2003 14:44 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.13/21

CERTIFICATE OF SERVICE

I hereby certify that a true and correct copy of the foregoing document has been forwarded via Regular United States Mail to all counsel of record on this ____ day of October, 2003.

Michael T. Scott
REED SMITH, L.L.P.
2500 One Liberty Place
Philadelphia, Pennsylvania 19103
Telephone: 215/851-8248
Facsimile: 215/851-1420

**LIASON COUNSEL OR FENFLURAMINE AND DEXFENFLURAMINE
DEFENDANTS**

Edward W. Madeira, Jr.
PEPPER HAMILTON, L.L.P.
Bell Atlantic Building, 34th Floor
1717 Arch Street
Philadelphia, Pennsylvania 19103
Telephone: 215/981-4353
Facsimile: 215/981-4307

LIASON COUNSEL FOR PHENTERMINE MANUFACTURERS AND SUPPLIERS

Edward S. Weltman
GOODWIN PROCTOR, L.L.P.
1285 Avenue of the Americas
New York, New York 10019
Telephone: 212/956-1500
Facsimile: 212/956-3252

CO-LEAD COUNSEL FOR PHENTERMINE DEFENDANTS

Peter L. Resnick
McDERMOTT, WILL & EMERY
28 State Street, 34th Floor
Boston, Massachusetts 02109-1775
Telephone: 617/535-4000
Facsimile: 617/535-3800

OCT 23 2003 14:44 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.14/21

CO-LEAD COUNSEL FOR PHENTERMINE DEFENDANTS

Mr. John J. Disimone, III
Plaintiffs' Management Committee
Diet Drugs Products Liability Litigation
325 Chestnut Street, Suite 200
Philadelphia, Pennsylvania 19106

PLAINTIFFS' MANAGEMENT COMMITTEE


SUSAN EARNEST

OCT 23 2003 14:44 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.15/21

**TECHNISCARDIACARDIOLOGICAL ASSOCIATES
A PROFESSIONAL MEDICAL CORPORATION**

Gabriel Lasala, M.D., F.A.C.C. Dorothy H. Bantsh, M.D., F.A.C.C. Frank Voelker, III, M.D.
Michael Lecce, M.D., F.A.C.C. Philip A. Gardner, M.D., F.A.C.S., RVT Richard Colón, M.D.
George E. Barnes, M.D., F.A.C.S.

ECHOCARDIOGRAPHIC REPORT

NAME: Marilyn Melder AGE: DATE: 1/15/98 TAPE:
PHYSICIAN: Dr. Lasala REFERRING PHYSICIAN:
DIAGNOSIS:

M-Mode Interpretation

RVDd _cm (1.7-2.7)	LVEF _% (>55%)
LVDd _cm (3.5-5.7)	LAD _cm (1.9-4.0)
LVDs _cm (2.6-3.9)	AO _cm (1.9-4.0)
IVSd _cm (0.6-1.2)	AoV vel (1.0-1.7 m/sec)
IVSs _cm (0.7-1.1)	AoV area _ (3-5 cm ²)
	MV PHT _ (30-60 msec)

Aortic valve:
Mitral valve: Thickening of interior leaflet.
Septal motion: Normal.
Posterior wall motion: Normal.
Quality of recording: Good.

2-D Interpretation

1. Normal LV size.
2. Normal LV systolic function with an ejection fraction of 65%.

Doppler Interpretation

3. Mild MR.
4. Mild AI.


Gabriel P. Lasala, M.D.
Cardiologist

DT: 10/22/03

OCT 23 2003 14:45 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.16/21

Tchefuncte Personal care
from
Cardiovascular
Associates cardiovascular specialists

Gabriel Lasala, M.D., F.A.C.C.
Michael LeCce, M.D., F.A.C.C.

Dorothy H. Bank, M.D., F.A.C.C.
Philip A. Gardner, M.D., F.A.C.S., RVT
George E. Barnes, M.D., F.A.C.S.

Frank Voelker III, M.D.
Richard Colon, M.D.

October 22, 2003

RE: Marilyn Melder

To Whom It May Concern:

I am a physician Board Certified in Cardiology, Interventional Cardiology, and Internal Medicine and have practiced cardiology in the state of Louisiana since 1995. I am Chief of Cardiology at Lakeview Regional Medical Center and treat patients who have cardiac disease. I have not testified as an expert at trial or by deposition within the preceding four years. The remainder of my qualifications and current publications are found in my curriculum vitae. My fee for depositions and trial testimony is \$500.00 per hour including travel time.

I was asked to interpret an echocardiogram on Marilyn Melder. My opinion expressed for her is based on my review of her echocardiogram tape and is contained in my report. The data and information I used in forming my opinion was based on the level of regurgitation as defined by Singh (1999).

The echocardiogram tape and accompanying report can be used as exhibits in support of my opinion.

Should you need any further information please don't hesitate to contact my office.

Sincerely,


Gabriel P. Lasala, M.D., F.A.C.C.

101 East Fairway Drive
Suite 504
Covington, Louisiana 70433
(985) 871-8227
(985) 871-1548 Fax

1117 South Tyler Street
Covington, Louisiana 70433
(985) 893-0090
(985) 893-9294 Fax

809 Boof Ramp Road
Franklinton, Louisiana 70438
(985) 839-6244
(985) 839-9842 Fax

537 Kentucky Avenue
Suite A
Bogalusa, Louisiana 70427
(985) 732-1660
(985) 732-1657 Fax

www.tchefunctecardio.com

OCT 23 2003 14:45 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.17/21

Gabriel P. Lasala, M.D., F.A.C.C.

Diplomate American Board of Internal Medicine in

Internal Medicine
Cardiovascular Diseases
Interventional Cardiology

Address: 803 Tradition Drive
Covington, LA 70433

Telephone: (985) 875-9985

Marital Status: Divorced

Children/DOB: Maria Florencia 01/26/85
Julieta 11/11/86
Nicholas Gabriel 01/03/94
Claudia Caroline 07/01/96

Social Security: 353-80-1401

Studies

High School: Liceo Militar G. Espejo. Colegio Nacional A. Alvarez.
Mendoza, Argentina 1973-1977

School of Medicine: National University of Cordoba.
Cordoba, Argentina 1978-1984

Degree Obtained: Physician and Surgeon 12-19-89

Medical License: Louisiana, 10402R
Mississippi, 13305

Native Language: Spanish Second Language: English

Updated: 6/5/02

OCT 23 2003 14:45 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.18/21

Gabriel P. Lasala, M.D.

Diplomate American Board of Internal Medicine in
Internal Medicine
Cardiovascular Diseases
Interventional Cardiology

Medical Exams:

FMGEMS (Foreign Graduate Examination in Medical Sciences) taken and passed 1988

The Medical Council of Canada: taken and passed 1985

Flex: Taken and passed 1990, Nashville, TN. Taken and passed 1992, Jackson, MS

American Board of Internal Medicine: Taken and passed 1992, New Orleans, LA

Cardiology Boards: Taken and passed 1995, Houston, TX

Interventional Cardiology Boards (ABIM): Taken and passed 1999, New Orleans, LA

Positions:

Anesthesiology: First year residency. Misericordia Hospital, Cordoba, Argentina. 1984

Internal Medicine: Posadas National Hospital, Buenos Aires, Argentina. 1985

Internal Medicine: Internship (3yrs). Posadas National Hospital, Buenos Aires, Argentina. 1986-1988

Emergency Medicine: Staff Member. Posadas National Hospital, Buenos Aires, Argentina. 1987-1988

Internal Medicine: Residency (3yrs). University of Mississippi Medical Center, Jackson, MS 1/89-1/92

Cardiology: Fellowship. University of Mississippi Medical Center, Jackson, MS. 1/92-1/95

Emergency Medicine: Active Staff. St. Dominic Jackson Memorial Hospital, Jackson, MS 1/93-3/95

Cardiology: Active Staff. Byrd Regional Hospital, Leesville, LA 2/95-9/97

Cardiology: Active Staff. St. Francis Cabrini Hospital, Alexandria, LA 4/95-9/97

Medical Director of Cardiac Catheterization Lab. Byrd Regional Hospital, Leesville, LA 1/95-9/97

Medical Director of ICU. Byrd Regional Hospital, Leesville, LA 1/97-9/97

Cardiology: Active Staff. St. Tammany Parish Hospital, Covington, LA 9/97-Present

Cardiology: Active Staff. Lakeview Regional Medical Center, Covington, LA 9/97-Present

Chief of Cardiology: St. Tammany Parish Hospital, Covington, LA 1/2001 and 1/2002

Chief of Cardiology: Lakeview Regional Medical Center, Covington, LA 1/2001 and 1/2002

Updated: 4/2003

OCT 23 2003 14:45 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.19/21

Gabriel P. Lasala, M.D.

Diplomate American Board of Internal Medicine in
Internal Medicine
Cardiovascular Diseases
Interventional Cardiology

Teaching:

Physiology: Assistant Instructor of Physiology. School of Medicine. National University of Cuyo 1981-1982

ACLS Instructor, American Heart Association. 2/94

Rotational Coronary Atherectomy: Proctor for Rotablator, Boston Scientific-SCIMED Corp. 4/00

Research:

Effects of beta-adrenergic blocker agents on vascular reactivity.
Dept of Pathophysiology, School of Medicine. National University of Cuyo. 1981-1982

Streptokinase in acute myocardial infarction. Posadas National Hospital, Buenos Aires, Argentina. 1987-1988

Mechanical Function of ex-vivo cold stored hearts with fructose 1-6 diphosphate. Division of Cardiology. University of Mississippi. 1989-1991

Plasma oxidase activity in the diagnosis of myocardial infarction. Division of Cardiology. University of Mississippi. 1990-1992

Publications:

- 1) J. Abdhala, M. Delugan, G. Perez Lasala. Effects of beta adrenergic blocker agents on vascular reactivity. Rev Univ 87,7;1998:84
- 2) G. Perez Lasala. Fibrinolytics in the treatment of acute Myocardial Infarction. Prensa Med Argentina 75;8, 1998:270-73
- 3) W. Bennet, L. Farias, G. Perez Lasala. Mechanical function of ex-vivo cold stored hearts is improved with fructose 1-6 diphosphate. Clinical Research. 38,1;1990:24A
- 4) G. Perez Lasala, R. Nolan, S. Chapman Peritoneal blastomycosis. Am j. Gastroent. 86,3;1991:357-359
- 5) T. Wright, L. Farias, G. Perez Lasala Plasma oxidase assay for diagnosis of myocardial infarction. Clinical Research 39, 4; 1991:790A
- 6) G. Perez Lasala, T. Cannon, K. Mansel. Lymphangitic carcinomatosis from cervical carcinoma. Am J Med Sci 303(3); 1992:174-76
- 7) E. Abbud, K. Osman, G. Perez Lasala. Possible mechanism for the appearance of J-wave on the electrocardiogram during hypothermia. Eur Heart J 13: (suppl); 1992:112
- 8) J.D. Cleary, J. Hayman, J. Sherwood, G. Perez Lasala, T. Piazza-Hopp. Amphotericin B overdose in pediatric patients with associated cardiac arrest. Ann Pharmacother. 27;1993:715-8
- 9) G. Perez Lasala, T. Wright, K. Osman, S. Slouffi, T. Skilton. Plasma oxidase assay for screening of myocardial infarction. Am J Med Sci 1994; 306(3): 157-161

OCT 23 2003 14:46 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.20/21

Gabriel P. Lasala, M.D.

Extramural American board of Internal Medicine in
Internal Medicine
Cardiovascular Diseases
Interventional Cardiology

Society Memberships:

American Society of Internal Medicine
American Medical Association
American College of Physicians
American college of Cardiology
Southern Medical Association

Presentations:

Effects of beta-adrenergic blocking agents in vascular reactivity.
Jornadas Nacionales de Investigacion. Mendoza, Argentina. 1984

Peritoneal Blastomycosis. American College of Physician. Louisiana and Mississippi Scientific Meeting.
Jackson, Mississippi. 1990

Plasma Oxidase Activity. Southern Society for Clinical Investigation. New Orleans, Louisiana. 1992

Plasma Oxidase assay for diagnosis of myocardial infarction. American College of Physicians, 73rd
Annual Session, San Diego, CA. 1992

Awards:

Certificate of merit. American College of Physicians: Participation in 1990 Associates Presentation.
Louisiana/Mississippi Chapters, Jackson, Mississippi.

Certificate of Merit. American College of Physicians: Selected Finalist 1992 National Associates
Research Poster Competition, San Diego, California

Fellowships:

American College of Cardiology

OCT 23 2003 14:46 FR ARNOLD PORTER

212 715 1397 TO **4779*02571190* P.21/21

Gabriel P. Lasala, M.D.

Diplomate American Board of Internal Medicine in
Internal Medicine
Cardiovascular Diseases
Interventional Cardiology

Clinical Trials:

Procter & Gamble Pharmaceuticals, Inc. Sub Investigator. Study Name: Multi-center double-blind, placebo-controlled, parallel design clinical trial to assess the efficacy and safety of a daily oral dose of 125 mg of Azimilide Dihydrochloride for the prophylactic treatment of symptomatic atrial fibrillation/flutter and/or symptomatic paroxysmal supraventricular tachycardia. Protocol No: 1998017. 1997-1998

Biogen. Principal Investigator. New Orleans Clinical Trial Management. 1998-1999

Procter & Gamble Pharmaceuticals, Inc. Sub Investigator. Study Name: Multi-center open-label clinical trial to assess the long term safety of a daily oral dose of 125 mg Azimilide Dihydrochloride in patients with atrial fibrillation/flutter and/or paroxysmal supraventricular tachycardia. Protocol No: 1998018. 1998 - present

Smith Kline Beecham, Lotrafiban - SB 214857. Sub Investigator. Study Name: Blockade of the GP IIb/IIIa Receptor to avoid vascular occlusion (BRAVO). Protocol No: 214857/030. 1999-2001

AstraZeneca. Sub Investigator. Study Name: Efficacy and safety study of the oral direct thrombin inhibitor H 976/95 compared with dose-adjusted Warfarin (Coumadin) in the prevention of stroke and systemic embolic events in patients with atrial fibrillation. (SPORTIF V) 2000-Present

Bristol-Myers Squibb (BMS). Sub Investigator. Study Name: Omapatrilat cardiovascular treatment assessment versus enalapril (OCTAVE). Protocol No: CV137-120. 2000-2001

Procter & Gamble Pharmaceuticals, Inc. Sub Investigator. Study Name: Randomized, double-blind, placebo-controlled study of two intravenous dosing regimens of h5G1.1-scFv in patients with acute myocardial infarction undergoing percutaneous transluminal coronary angioplasty reperfusion therapy (COMMA). Protocol No: 1999053. 2000-2002

Procter & Gamble Pharmaceuticals, Inc. Sub Investigator. Study Name: Randomized, double-blind, placebo-controlled study of two intravenous dosing regimens of h5G1.1-scFv in patients with acute myocardial infarction undergoing thrombolytic reperfusion therapy (COMPLY). Protocol No: 1999052. 2000-2002

Updated: 6/5/02

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a true and correct copy of Wyeth's Motion to Strike Plaintiffs Marilyn Melder's and Peggy Martinez's Expert Witnesses and to Bar Plaintiff Tefferny Perez from Designating an Expert was served this 9th day of December 2003 by UPS Overnight Delivery upon counsel in the foregoing action addressed as follows:

Robert G. Harvey, Sr., Esq.,
Harvey Jacobson & Glago, APLC
2609 Canal Street, Fifth Floor
New Orleans, LA 70119

Richard N. Laminack, Esq.
Buffy Martines
O'Quinn, Laminack & Pirtle
440 Louisiana, Suite 2400
Houston, TX 77002

Darleen Jacobs, Esq.
Jacobs & Sarrat
823 St. Louis Street
New Orleans, LA 70112

Susan Earnest, Esq.
Diet Drugs Litigation
2752 Canal Street
New Orleans, LA 70119

and by U.S. first-class mail, postage prepaid, upon counsel required to be served by Pretrial Order No. 19.


Caroline Flotron, Esquire

Date: December 9, 2003